drugset / Trial / NCT00413426

Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects

NCT00413426

Phase 1 Completed 28 enrolled Novartis Procter and Gamble · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This purpose of this study is to compare the how the body changes the blood level of a single dose of darifenacin when given as 7.5 mg modified release tablet and the modified release liquid suspension (1.5 mg/ml) under fasted and fed conditions in healthy subjects.

Timeline

Start
2006-06
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 7.5 mg Oral

Indications

No indication recorded.